Patients who take prescription opioids for chronic pain may have difficulty receiving treatment as new patients at primary care clinics.
Online symptom self-management plus clinician telecare can be effective for individuals with pain, depression, and anxiety.
In addition to being manufactured outside of the controls required by current Good Manufacturing Practices, these products are also being marketed for diseases without FDA approval.
According to the findings of a recent review, the Food and Drug Administration rarely disagrees with recommendations made by its advisory committees.
Rates of opioid administration were found to be high in opioid-naive inpatients.
Investigators sought to determine how frequently information treated as confidential with regard to New Drug Applications or Biologics License Applications is available to the public.
As part of current efforts to reduce unnecessary opioid consumption, clinicians have increasingly prescribed gabapentinoids for a range of pain disorders.
The FDA is looking to make the information in the Drug Abuse and Dependence section of product labeling more consistent and clear through a new draft guidance.
A man presents to the emergency department with progressive, right-sided abdominal and flank pain for 3 days.
The use of cannabidiol (CBD), the non-intoxicating component of cannabis, has been associated with numerous adverse effects based on available evidence from animal and human studies.